FDA approves 1st non-opioid treatment for management of opioid withdrawal symptoms

The US Food and Drug Administration yesterday approved Lucemyra (lofexidine hydrochloride) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. It is approved for treatment for up to 14 days only, is not a treatment for opioid use disorder, but can be used as part of a broader, long-term treatment plan.